Skip to main content
SpringerLink
Log in

Drug-Induced Torsade de Pointes

Incidence, Management and Prevention

  • Review Article
  • Pharmacoepidemiology
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Torsade de pointes is a particular form of polymorphic ventricular tachycardia causing few haemodynamic symptoms, but carries a poor prognosis because of recurrence and sudden death in up to 31% of patients. A wide range of agents have been shown to aggravate and even to cause torsade de pointes by prolonging the QT interval or increasing QT dispersion. For the majority of substances the incidence of torsade de pointes remains unclear, but is of the order of 3 to 15% for a wide range of agents. Elicitation of proarrhythmia by drug-induced QT prolongation is mainly based on increased cellular excitability and/or abnormal dispersion of ventricular repolarisation. Torsade de pointes has been shown to be related to bradycardia-dependent early after-depolarisations and/or increased dispersion of repolarisation. Clinically, patients with predisposing factors prior to medication should be considered at risk of drug-mediated proarrhythmia. Typically, torsade de pointes occurs during the first days of antiarrhythmic therapy. During this phase, QT interval measurement and assessment of the QTc time should be performed frequently. Phases of bradycardia or occurrence of ventricular extra beats with a long coupling interval may be of help to identify patients at high risk of proarrhythmic events.

As a first attempt in managing this arrhythmia, magnesium sulphate has been shown to be effective in many patients. In case of recurrence of torsade de pointes, the use of a temporary pacemaker with pacing at about 100 to 120 beats/min is the therapy of choice until the causative agent has been completely eliminated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dessertenne F. Un chapitre nouveau d’electrocardiographic: les variations progressives de l’amplitude de l’electrocardio-gramme. Actual Cardiol Angiol Int 1966; 15: 241–58

    CAS  Google Scholar 

  2. Dessertenne F. La tachycardia ventriculaire a deux foyers opposes variable. Arch Mal Coeur Vaiss 1966; 59: 263–72

    PubMed  CAS  Google Scholar 

  3. Sasyniuk BI, Valois M, Toy W. Recent advances in understanding the mechanisms of drug-induced torsades de pointes arrhythmias. Am J Cardiol 1989; 64 (20): 29J–32J

    PubMed  CAS  Google Scholar 

  4. Abildskov JA. Effects of activation sequence on local recovery of ventricular excibility in the dog. Circ Res 1976; 38: 240–3

    PubMed  CAS  Google Scholar 

  5. Abildskov JA. The ventricular gradient and repolarization. Jpn Heart J 1986; 27: 197–204

    PubMed  Google Scholar 

  6. Day CP, McComb JM, Campbell RWF. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990; 63: 342–4

    PubMed  CAS  Google Scholar 

  7. Hii JTY, Wyse DG, Gillis AM, et al. Precordial QT interval dispersion as a marker of torsade de pointes. Disperate effects of class la antiarrhythmic drugs and amiodarone. Circulation 1992; 86; 1376–82

    PubMed  CAS  Google Scholar 

  8. Bonatti V, Rolli A, Botti G. Recordings of monophasic action potentials of the right ventricle in long QT syndromes complicated by severe ventricular arrhythmias. Eur Heart J 1983; 4: 167–79

    Google Scholar 

  9. Singh BN. When is QT prolongation antiarrhythmic and when is it proarrhythmic? Am J Cardiol 1989; 63: 867–9

    PubMed  CAS  Google Scholar 

  10. Selzer A, Wray HW. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964; 30: 17–26

    PubMed  CAS  Google Scholar 

  11. Jackman WM, Friday KJ, Anderson JL, et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31: 115–72

    PubMed  CAS  Google Scholar 

  12. Roden DM. The long QT syndrome and torsade de pointes: basic and clinical aspects. In: El-Sharif N, Samet P, editors. Cardiac pacing and electrophysiology. Philadelphia: Saunders Company, 1991: 265–84

    Google Scholar 

  13. Kay GN, Plumb VJ, Arciniegas JG, et al. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 1983; 2: 806–17

    PubMed  CAS  Google Scholar 

  14. Hohnloser SH, Arendts W, Quart B. Torsade de pointes during sotalol therapy [abstract]. Eur Heart J 1992; 13 Suppl.: 305

    Google Scholar 

  15. Jorens PG, Vandden Heuvel, Ranquin R, et al. Amiodarone induced torsade de pointes. Report of three cases and review of literature. Acta Cardiol 1989; 44: 411–21

    PubMed  CAS  Google Scholar 

  16. Moore MT, Book MH. Sudden death in phenothiazine therapy. Aclinicopathologic study of 12 cases. Psychiatr Q 1970; 44: 384–402

    Google Scholar 

  17. Schoonmaker FW, Osten RT, Greenfiled Jr JC. Thioridazine (‘Melleril’) induced ventricular tachycardia controlled with an artificial pacemaker. Ann Intern Med 1966; 65: 1076–8

    PubMed  CAS  Google Scholar 

  18. Guelon D, Bedock B, Chartier C, et al. QT prolongation and recurrent ‘Torsade de pointes’ during erythromycin lactobion-ate infusion. Am J Cardiol 1987; 59: 168–9

    Google Scholar 

  19. McComb JB, Campbell NPS, Clelend J. Recurrent ventricular tachycardia with QT prolongation after initial valve replacement and its association with intravenous administration of erythromycin. Am J Cardiol 1984; 54: 922–3

    PubMed  CAS  Google Scholar 

  20. Nattel S, Ranger S, Talajic M, et al. Erythromycin-induced long QT syndrome: concordance withquinidine and underlaying cellular electrophysiologic mechanism. Am J Med 1990; 89: 235–8

    PubMed  CAS  Google Scholar 

  21. Stramba-Badiale M, Guffanti S, Porta N, et al. QT interval prolongation and cardiac arrest during therapy with spiramycin in a new-born infant. Am Heart J 1993; 126: 740–2

    PubMed  CAS  Google Scholar 

  22. Baumann JL, Pharm D, Bauernfeind RA, et al. Torsade de pointes due to quinidine: observations in 31 patients. Am Heart J 1984; 107: 425–30

    Google Scholar 

  23. Keren A, Tzivoni D, Gavish D. Etiology, warning signs and therapy of torsade de pointes: a study of 10 patients. Circulation 1981; 64: 1167–74

    PubMed  CAS  Google Scholar 

  24. Dyckner F, Wester PO. Ventricular extrasystoles and intracellular electrolytes before and after potassium and magnesium infusions in patients on diuretic treatment. Am Heart J 1979; 97 (1): 12–8

    PubMed  CAS  Google Scholar 

  25. Kurita T, Ohe T, Marui N, et al. Bradycardia-induced abnormal QT prolongation in patients with complete atrioventricular block with torsade de pointes. Am J Cardiol 1992; 69: 628–33

    PubMed  CAS  Google Scholar 

  26. Strasberg B, Kusniec J, Erdmann S, et al. Polymorphous ventricular tachycardia and atrioventricular block. PACE Pacing Clin Electrophysiol 1986; 9: 522–6

    PubMed  CAS  Google Scholar 

  27. Curry P, Fitchett D, Stubbes W, et al. Ventricular arrhythmias and hypokalaemia. Lancet 1976; 2: 231–3

    PubMed  CAS  Google Scholar 

  28. Campbell TJ. Proarrhythmic actions of antiarhythmic drugs: a review. Aust N Z J Med 1990; 20 (3): 275–82

    PubMed  CAS  Google Scholar 

  29. Kahn MN, Logan KR, McComb JM, et al. Management of recurrent ventricular tachyarrhythmias associated with QT prolongation. Am J Cardiol 1981; 47: 1301–8

    Google Scholar 

  30. Napolitano C, Bonazzi O, Diehl L, et al. Dispersion of ventricular activation in the long QT syndrome. Circulation 1992; 86 Suppl. I: 391

    Google Scholar 

  31. Damiano BP, Rosen MR. Effects of pacing on triggered activity induced by early afterdepolarizations. Circulation 1984; 68: 1013–25

    Google Scholar 

  32. January CT, Shorofsky S. Early afterdepolarizations: newer insight into cellular mechanisms. J Cardiovasc Electrophysiol 1990; 1: 161–9

    Google Scholar 

  33. Schwartz PJ, Locati E, Priori SG, et al. The long QT syndrome. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology. From cell to bedside. Philadelphia: Saunders Company, 1990: 589–605

    Google Scholar 

  34. Surawicz B. Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations. J Am Coll Cardiol 1989; 14: 172–84

    PubMed  CAS  Google Scholar 

  35. Cranefield PF. Action potentials, afterpotentials and arrhythmias. Circ Res 1977; 41: 415–23

    PubMed  CAS  Google Scholar 

  36. Henning B, Wit AL. The time course of action potential repolarization affects delayed afterdepolarization amplitude in atrial fibres of the canine coronary sinus. Circ Res 1984; 55: 110–5

    PubMed  CAS  Google Scholar 

  37. Levine JH, Spear JF, Guarnieri T, et al. Cesium chloride-induced long QT syndrme: Demonstration of afterdepolarizations and triggered activity in vivo. Circulation 1985; 72 (5): 1092–103

    PubMed  CAS  Google Scholar 

  38. Morgan JM, Lopes A, Rowland E. Sudden cardiac death while taking amiodarone therapy: the role of abnormal repolarization. Eur Heart J 1991; 12 (10): 1144–7

    PubMed  CAS  Google Scholar 

  39. Weissenburger J, Davy JM, Chezalviel F. Experimental models of torsade de pointes. Fundam Clin Pharmacol 1993; 7 (1): 29–38

    PubMed  CAS  Google Scholar 

  40. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986; 111: 1088–93

    PubMed  CAS  Google Scholar 

  41. Isner JM, Sours HE, Paris AL, et al. Sudden, unexpected death in avid dieters using the liquid-protein-modified-fast diet. Observations in 17 patients and the role of prolonged QT interval. Circulation 1979; 6: 1401–12

    Google Scholar 

  42. Brachmann J, Scherlag BJ, Rosenshtraukh LV. Bradycardia-depent triggered activity. Relevance to drug-induced multiform ventricular tachycardia. Circulation 1983; 68: 846–56

    PubMed  CAS  Google Scholar 

  43. Zehender M, Meinertz T, Hohnloser S, et al. The Multicenter Ketanserin Research Group. Incidence and clinical relevance of QT prolongation caused by the selective serotonin antagonist ketanserin. Am J Cardiol 1989; 63: 826–32

    PubMed  CAS  Google Scholar 

  44. Denker P, Lehmann M, Mahmud R, et al. Facilitation of ventricular tachycardia induction with abrupt changes in ventricular cycle length. Am J Cardiol 1984; 53: 508–15

    PubMed  CAS  Google Scholar 

  45. Yoon MS, Han J, Dersham GH, et al. Effects of thioridazine (Mellaril) on ventricular electrophysiologic properties. Am J Cardiol 1979; 43: 1155–8

    PubMed  CAS  Google Scholar 

  46. Roden DM, Hoffmann BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibres. Relationship to potassium and cycle length. Circ Res 1985; 56: 857–67

    PubMed  CAS  Google Scholar 

  47. Faber TS, Zehender M, Van de Loo A, et al. Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmias: four case reports. Clin Cardiol 1994; 17: 197–202

    PubMed  CAS  Google Scholar 

  48. Cardiac Arrhythmia Suppression Trial (CAST) investigators. Preliminary report: effects of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406–12

    Google Scholar 

  49. Wolfe CL, Nibley C, Bhandari A, et al. Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation 1991; 84: 1543–51

    PubMed  CAS  Google Scholar 

  50. Schwartz PJ, Wolf S. QT interval prolongation as a predictor of sudden death in patients with myocardial infarction. Circulation 1978; 57: 1074–7

    PubMed  CAS  Google Scholar 

  51. Zehender M, Hohnloser S, Just H. QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards. Cardiovasc Drugs Ther 1991; 5: 515–30

    PubMed  CAS  Google Scholar 

  52. Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes. Mechanisms and management. Drugs 1994; 47 (1): 51–65

    CAS  Google Scholar 

  53. Bhandari AK, Shapiro WA, Morady F, et al. Electrophysiologic testing in patients with the long QT syndrome. Circulation 1985; 71: 63–71

    PubMed  CAS  Google Scholar 

  54. Roden DM. Torsade de pointes. Clin Cardiol 1993; 16: 683–6

    PubMed  CAS  Google Scholar 

  55. Motte G. True and false torsade de pointes [letter]. Am Heart J 1985; 6: 1404

    Google Scholar 

  56. Tzivoni D, Keren A, Stern S. Torsade depointes versus polymorphous ventricular tachycardia. Am J Cardiol 1983; 52: 639–40

    PubMed  CAS  Google Scholar 

  57. Wit AL. Cellular electrophysiologic mechanism of cardiac arrhythmias. Ann NY Acad Sci 1984; 432: 1–16

    PubMed  CAS  Google Scholar 

  58. Nguyen PT, Scheinmann MM, Seger J. Polymorphous ventricular tachycardia: clinical characterization, therapy and the QT interval. Circulation 1986; 74: 340–9

    PubMed  CAS  Google Scholar 

  59. Bhandari AK, Scheinmann M. The long QT syndrome. Mod Concepts Cardiovasc Dis 1985; 54: 45

    Google Scholar 

  60. Mattioni TA, Zheutlin TA, Sarmiento JJ, et al. Amiodarone in patients with previous drug-mediated torsade de pointes. Ann Intern Med 1989; 111: 574–80

    PubMed  CAS  Google Scholar 

  61. Lazzara R. Amiodarone and torsade de pointes. Ann Intern Med 1989; 111: 549–51

    PubMed  CAS  Google Scholar 

  62. Roden DM. Arrhythmogenic potential of class III antiarrhythmic agents: comparison with class I agents. In: Singh BN, editor. Control of cardiac arrhythmias by lengthening repolarization. Mount Kisco: Futura Publishing Co., 1988: 559–77

    Google Scholar 

  63. Bhandari AK, Scheinmann M. Torsade de pointes: is the term necessary? In: Butrous GS, Schwartz P, editors. Clinical aspects of ventricular repolarization: part III. London: Farrand Press, 1989: 305

    Google Scholar 

  64. Butrous GS, Dabbas NM, Patel PR, et al. Measurement of the OT interval. In: Butrous GS, Schwartz P, editors. Clinical aspects of ventricular repolarization: part I. London: Farrand Press, 1989: 41–8

    Google Scholar 

  65. Haynes RE, Hallstrom HP, Cobb LA. Repolarization abnormalities in survivors of out-of-hospital ventricular fibrillation. Circulation 1978; 57: 654–8

    PubMed  CAS  Google Scholar 

  66. Lepeschkin E, Surawicz B. The duration of the Q-U interval and its component in electrocardiograms of normal persons. Am Heart J 1953; 46: 9–20

    PubMed  CAS  Google Scholar 

  67. Bonatti V, Rolli A, Finardi A, et al. Mechanisms and clinical relevance of QT prolongation and related arrhythmias. In: Butrous GS, Schwartz P, editors. Clinical aspects of ventricular repolarization. London: Farrand Press, 1989: 305

    Google Scholar 

  68. Day CP, McComb JM, Matthews J, et al. Reduction in QT dispersion by sotalol following myocardial infarction. Eur Heart J 1991; 12: 423–7

    PubMed  CAS  Google Scholar 

  69. Simpson GG, Roe A, Lewontin RC. Quantitative zoology. New York: Harcourt, Brace & Jovanovich, 1969: 440

    Google Scholar 

  70. Dritsas A, Gilligan D, Nihoyannopoulos P, et al. Amiodarone reduces QT dispersion in patients with hypertrophic cardiomyopathy. Int J Cardiol 1992; 36: 345–9

    PubMed  CAS  Google Scholar 

  71. Singh BN, Nademanee K. Sotalol: a beta blocker with unique antiarrhythmic properties. Am Heart J 1987; 114: 1040–50

    PubMed  CAS  Google Scholar 

  72. Vaughan William EM. QT and action potential duration. Br Heart J 1982; 47: 513–4

    Google Scholar 

  73. Vaughan William EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984; 24: 129–47

    Google Scholar 

  74. Stanton MS, Prystowsky EN, Fineberg NS, et al. Incidence of ventricular tachycardia and ventricular fibrillation as pro-arrhymic effects during treatment of ventricular arrhythmia. J Am Coll Cardiol 1987; 9: 945)A

    Google Scholar 

  75. Koster RW, Wellens HJJ. Quinidine-induced ventricular flutter and fibrillation without digitalis therapy. Am J Cardiol 1976; 38: 519–23

    PubMed  CAS  Google Scholar 

  76. Späth G. Vergiftungen und akute Arzneimittelüberdosierungen. Verlag Gerhard Witzstrock Baden-Baden: Verlag de Gruy-ter, 1978

  77. Lown B, Graboys TB. Management of patients with malignant ventricular arrhythmias. Am J Cardiol 1977; 39: 910–8

    PubMed  CAS  Google Scholar 

  78. Storstein O. Syncope and sudden death as a side effect of treatment with antiarrhthmic drugs. In: Sandoe E, Flensted-Jensen E, Olesen KH, editors. Symposium on cardiac arrhythmias; 1970 April 23–25: Elsinore, Denmark. Stockholm: AB Astra, 1970: 505

  79. Hai H, Sato F. The high incidence of quinidine-induced aggravation of ventricular arrhythmias at low therapeutic blood levels. Circulation 1987; 57 Suppl. 2: 435

    Google Scholar 

  80. Podrid PJ. Can antiarrhythmic drugs cause arrhythmia? J Clin Pharmacol 1984; 24: 313–8

    PubMed  CAS  Google Scholar 

  81. Breithardt G, Seipel L, Haerten K. Paradoxe reaktion nach dis-opyeamid und Chinidin. Z Kardiol 1980; 69: 556–61

    PubMed  CAS  Google Scholar 

  82. Casedevant B, Sabaut D, Clementy J, et al. Syncopes par torsades de pointes en rapport avec la prise de Disopyramide. Nouv Presse Med 1975; 4: 2339

    PubMed  CAS  Google Scholar 

  83. Dibble JB, Webster NR. Adverse reaction to disopyramide. Postgrad Med J 1979; 55: 570–2

    PubMed  CAS  Google Scholar 

  84. Lo KS, Gantz KB, Stetson PL, et al. Disopyramide-induced ventricular tachycardia. Arch Intern Med 1980; 140: 413–4

    PubMed  CAS  Google Scholar 

  85. Miura DS, Rosen MR. New directions in the development of antiarrhythmic drugs. J Clin Pharmacol 1984; 24: 333–41

    PubMed  CAS  Google Scholar 

  86. Campbell TJ. Subclassification of class Ia antiarrhythmic drugs. In: Vaughan Williams ED, editor. Antiarrhythmic drugs. New York: Springer Verlag, 1989: 135

    Google Scholar 

  87. Hoffman BF, Rosen JR, Wit AL. Electrophysiology and pharmacology of cardiac arrhythmias. VII. Cardiac effects of quinidine and procainamide. Am Heart J 1975; 89: 804–9

    PubMed  CAS  Google Scholar 

  88. Rosen MR, Gelband H, Merker C. Effects of procainamide on the electrophysiologic properties of the canine ventricular conducting system. J Pharmacol Exp Ther 1973; 185: 438–44

    PubMed  CAS  Google Scholar 

  89. Sclarovsky S, Strasberg B, Lewin RF, et al. Polymorphous ventricular tachycardia: clinical features and treatment. Am J Cardiol 1979; 44 (2): 339–44

    Google Scholar 

  90. Muhiddin K, Nathan AW, Hellestrand KJ, et al. Ventricular tachycardia associated with flecainide. Lancet 1983; 2: 1220–1

    Google Scholar 

  91. Conolly SJ, Kates RE, Lebsack CS, et al. Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. Am J Cardiol 52: 1209–13

  92. Seipel L, Breithardt G. Propafenone — a new antiarrhythmic drug. Eur Heart J 1988; 1: 309–13

    Google Scholar 

  93. Nathan AW, Bexton RS, Hellestrand KJ, et al. Fatal ventricular tachycardia in association with propafenone, a new class Ic antiarrhythmic agent. Postgrad Med J 1984; 60: 155–6

    PubMed  CAS  Google Scholar 

  94. Hii JT, Wyse DG, Gillis AM, et al. Propafenone-induced torsade de pointes: cross-reactivity with quinidine. PACE Pacing Clin Electrophysiol 1991; 14: 1568–70

    PubMed  CAS  Google Scholar 

  95. Olsson SB. Class III antiarrhythmic action. In: Vaughan Williams EM, editor. Antiarrhythmic drugs. New York: Springer Verlag, 1989: 323

    Google Scholar 

  96. Singh BN. Control of cardiac arrhythmias by lengthening repolarization. Mount Kisco: Futura Publishing Co, 1988

    Google Scholar 

  97. Sclarovsky S, Lewin RF, Kracoff O, et al. Amiodarone-induced polymorphous ventricular tachycardia. Am Heart J 1983; 105: 6–12

    PubMed  CAS  Google Scholar 

  98. Keren A, Tzivoni D, Gottlieb S, et al. Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone. Chest 1982; 81: 384–6

    PubMed  CAS  Google Scholar 

  99. Brown MA, Smith WM, Lubbe WF, et al. Amiodarone-induced torsades de pointes. Eur Heart J 1986; 7: 234–9

    PubMed  CAS  Google Scholar 

  100. Veglia L, Scandifflio T, Guerricchio G. Torsioni di punta e amiodarone. G Ital Cardiol 1987; 8: 1025–8

    Google Scholar 

  101. McComb JM, Logan KR, Khan MM, et al. Amiodarone induced ventricular fibrillation. Eur J Cardiol 1980; 11: 381–5

    PubMed  CAS  Google Scholar 

  102. Mattioni TA, Zheutlin TA, Dunnington C, et al. The pro-arrhythmic effects of amiodarone. Prog Cardiovasc Dis 1989; 6: 439–46

    Google Scholar 

  103. Tartini R, Klappenberger L, Steinbrunn W. Gefährliche Interaktionen zwischen Amiodaron und Antiarrhythmika der Klasse I. Schweiz med Wochenschr 1982; 112: 1585–7

    PubMed  CAS  Google Scholar 

  104. Hohnloser SH, Arendts W, Quart B, et al. Incidence, type and dose-dependence of proarrhythmic events during Sotalol therapy in patients treated for sustained VT/VF [abstract]. PACE Pacing Clin Electrophysiol 1992; 15: 551

    Google Scholar 

  105. Neuvonen PJ, Elonen E, Vuorenmaa T, et al. Prolonged Q-T interval and ventricular tachyarrhythmias: common features of Sotalol intoxication. Eur J Clin Pharmacol 1981; 20: 85–9

    PubMed  CAS  Google Scholar 

  106. Belton P, Sheridan J, Mulcahy R. A case of Sotalol poisoning. Ir J Med Sci 1982; 151: 126–7

    PubMed  CAS  Google Scholar 

  107. Kontopoulos A, Filindris A, Manoudis F, et al. Sotalol-induced torsade de pointes. Postgrad Med J 1981; 57: 321–3

    PubMed  CAS  Google Scholar 

  108. Kuck KH, Kinze KR, Roewer N, et al. Sotalol-induced torsade de pointes. Am Heart J 1984; 107: 179–80

    PubMed  CAS  Google Scholar 

  109. Minderjahn KP, Linnartz G, Münch H, et al. Sotalol induziertes long QT-Syndrom mit malignen ventrikulären Rhythmusstörungen (Torsade depointes). Bericht über 2 Fälle. In-tensivmed 1986; 23: 113–5

    Google Scholar 

  110. Montagna M, Groppi A. Fatal Sotalol poisoning. Arch Toxicol 1980 43: 221–6

    PubMed  CAS  Google Scholar 

  111. Neuvonen PJ, Elonen E, Tarasanen L. Sotalol intoxication, two patients with concentration-effect relationships. Acta Pharmacol Toxicol 1979; 45: 52–7

    CAS  Google Scholar 

  112. McKibben JK, Pocock WA, Barlow JB, et al. Sotalol, hypokalemia, syncope and torsade de pointes. Br Heart J 1984; 51: 157–62

    Google Scholar 

  113. Bennet JM, Gourassas J, Konstantinides S. Torsade de pointes induced by sotalol and hypokalemia. S Afr Med J 1985; 68: 591–2

    Google Scholar 

  114. Laakso M, Pertikainen PH, Lampainen E. Sotalol, prolonged Q-T interval and ventricular tachyarrhythmias. Ann Clin Res 1981; 13: 439–40

    PubMed  CAS  Google Scholar 

  115. Echt DS, Amstrong K, Schmidt P, et al. Clinical experience, complications, and survival in 70 patients with the automatic implantable caredioverter/defibrillator. Circulation 1985; 71: 289–96

    PubMed  CAS  Google Scholar 

  116. Laakso M, Pertikainen PH, Pyörola K, et al. Prolongation of the QT interval caused by sotalol-possible association with ventricular tachyarrhythmias. Eur Heart J 1981; 2: 353–8

    PubMed  CAS  Google Scholar 

  117. Echt DS, Lee JT, Murray KT, et al. A randomized, double-blind, placebo-controlled dose-ranging study of intravenous UK-68,798 (dofetilide) in patients with inducible sustained ventricular tachyarrhythmias [abstract]. Circulation 1991; 84 Suppl. 2: 714

    Google Scholar 

  118. Wong W, Pavlou HN, Birgersdotter UM, et al. Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias. Am J Cardiol 1992; 69: 206–12

    PubMed  CAS  Google Scholar 

  119. Sedgwick ML, Rasmussen HS, Cobbe SM. Clinical and electrophysiologic effects of intravenous dofeilide (UK-68, 798), a new class III antiarrhythmic drug, in patients with angina pectoris. Am J Cardiol 1992; 69: 513–7

    PubMed  CAS  Google Scholar 

  120. Gwilt M, Dalyrymple H, Burges RA, et al. UK-68,798 is a novel potent and selective class III antiarrhythmic drug. J Mol Cell Cardiol 1989; 21 Suppl. II: S11

    Google Scholar 

  121. Rae AP. Proarrhythmic responses during electrophysiologic testing. Cardiol Clin 1986; 4: 487–96

    PubMed  CAS  Google Scholar 

  122. Suttorp MJ, Polak PE, van’t Hof A, et al. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. Am J Cardiol 1992; 69: 417–9

    PubMed  CAS  Google Scholar 

  123. Tande PM, Bjornstad H, Yang T, et al. Rate-dependent class III antiarrhythmic action, negative chronotropy and positive in-otropy of a novel Ik blocking drug. UK-68,798: potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol 1990; 16: 401–10

    PubMed  CAS  Google Scholar 

  124. Gwilt M, Arrowsmith JE, Blackburn KJ, et al. UK-68,798: a novel potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J Pharmacol Exp Ther 1991; 256: 318–24

    PubMed  CAS  Google Scholar 

  125. Gascho JA, Schieken R. Congentital complete heart block and long Q-T syndrome requiring ventricular pacing for control of refractory ventricular tachycardia and fibrillation. J Electrocardiol 1979; 12: 331–5

    PubMed  CAS  Google Scholar 

  126. Engrav MB, Coodley G, Magnusson AR. Torsade de pointes after inhaled pentamidine. Ann Emerg Med 1992; 21 (11): 1403–5

    PubMed  CAS  Google Scholar 

  127. Gonzalez A, Sager PT, Akil B, et al. Pentamidine-induced torsade de pointes. Am Heart J 1991; 122: 1489–92

    PubMed  CAS  Google Scholar 

  128. Mason JW, Hondeghem LM. Quinidine. Ann NY Acad Sci 1984; 432: 162–8

    PubMed  CAS  Google Scholar 

  129. Rubart M, Pressler ML, Pride HP, et al. Electrophysiological mechanism in a canine model of erythromycin-associated long QT syndrome. Circulation 1993; 88: 1832–44

    PubMed  CAS  Google Scholar 

  130. Brochier M, Fauchier JP. Torsades de pointe et retreés provoqueés par les antiarythmiques. Arch Mal Coeur Vaiss 1978; 71: 477–88

    PubMed  CAS  Google Scholar 

  131. Sartori M, Peratt CM, Young JB. Torsade de pointes, malignant cardiac arrhythmia induced by amantadine poisoning. Am J Med 1984; 77: 388–91

    PubMed  CAS  Google Scholar 

  132. Conn HO, Ramsby GR, Storer EH. Selective intraarterial vas-opresin in the treatment of upper gastrointestinal hemorrhage. Gastroenterology 1972; 63: 634–45

    PubMed  CAS  Google Scholar 

  133. Stein LB, Debezies MA, Silverman M, et al. Fatal torsade de pointes occurring in a patient receiving intravenous vasopressin and nitroglycerin. J Clin Gastroenterol 1992; 15 (2): 171–4

    PubMed  CAS  Google Scholar 

  134. Craft TM. Torsade de pointes after astemizol overdose. BMJ 1986; 292: 660–8

    PubMed  CAS  Google Scholar 

  135. Woosley R, Chen Y, Freiman J, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532–6

    PubMed  CAS  Google Scholar 

  136. List WFM. Succinylcholine-induced cardiac arrhythmias. Anesth Analg Curr Res 1971; 50: 361–7

    CAS  Google Scholar 

  137. Blanloeil Y, Pinaud M, Nicolas F. Torsades de pointe après injection de suxaméthonium chez deux coronariens digitalisés. Nouv Presse Med 1979; 21 (8): 1765

    Google Scholar 

  138. Deveze JL, Sainty JM, David J. Intoxication volontaire au Fenoxedil. Nouv Presse Med 1976; 5: 23

    Google Scholar 

  139. Mettauer B, Rouleau JL, Burgess JH. Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure. Am Heart J 1985; 109: 840–8

    PubMed  CAS  Google Scholar 

  140. Roizen MF, Stevens WC. Multiform ventricular tachycardia due to the interaction of aminophylline and halothane. An-aesth Analg 1978; 57: 738–41

    CAS  Google Scholar 

  141. Moeschlin S. Klinik und Therapie der Vergiftungen. Stuttgart: Georg Thieme Verlag, 1986

    Google Scholar 

  142. Späth G. Torsade de pointes. Wien: Überreuter Wissenschaftsverlag, 1988

    Google Scholar 

  143. Gohn DC, Simmons TW. Polymorphic ventricular tachycardia (torsade de pointes) associated with the use of probucol. N Engl J Med 1992; 326 (21): 1435–6

    PubMed  CAS  Google Scholar 

  144. Haverkamp W, Hördt M, Hindricks G, et al. QT-Syndrome und Torsade de pointes. Intensivmed 1993; 30: 119–29

    Google Scholar 

  145. Hartzler GO, Osborn MJ. Invasive electrophysiologic study in the Jervell and Länge-Nielsen syndrome. Br Heart J 1981; 45: 225–9

    PubMed  CAS  Google Scholar 

  146. Tzivoni D, Keren A, Cohen AM, et al. Magnesium therapy of torsade de pointes. Am J Cardiol 1984; 53: 528–30

    PubMed  CAS  Google Scholar 

  147. Motoe K, Saku K, Tashiro N, et al. Torsade de pointes and atrioventricular block. Clin Cardiol 1988; 11: 9–13

    Google Scholar 

  148. Lansman JB, Hess P, Tsien RW. Blockade of current through the single calcium channels by Cd++, Mg++, Ca++. J Gen Physiol 1987; 88: 321–47

    Google Scholar 

  149. Bailie DS, Inoue H, Kaseda S, et al. Magnesium suppression of early afterdepolarizations and ventricular arrhythmias induced by caesium in dogs. Circulation 1988; 77: 1395–402

    PubMed  CAS  Google Scholar 

  150. Stern S, Keren A, Tzivoni D. Torsade de pointes: definition, causative factors and therapy. Experience with sixteen patients. Ann NY Acad Sci 1984; 427: 234–40

    PubMed  CAS  Google Scholar 

  151. Roden DM, Iansmith DHS, Woosley RL. Frequency-dependent interactions of mexiletine and quinidine in canine cardiac Purkinje fibres. J Pharm Exp Ther 1987; 243: 1218–24

    CAS  Google Scholar 

  152. Maloney JD, Nissen RG, McColgan BS. Open clinical studies at a referral centre. Chronic maintenance tocainide therapy in patients with recurrent sustained ventricular tachycardia refractory to convential antiarrhythmic agents. Am Heart J 1980; 100: 1023–30

    PubMed  CAS  Google Scholar 

  153. Shah A, Schwartz H. Mexiletine for treatment of torsade de pointes. Am Heart J 1984; 107: 589–91

    PubMed  CAS  Google Scholar 

  154. Jackman WM, Szabo B, Friday KJ, et al. Ventricular tachyarrhythmias related to early afterdepolarizations and triggered firing: relationship to QT interval prolongation and potential therapeutic role for calcium channel blocking agents. J Car-diovasc Electrophysiol 1990; 1: 170–95

    Google Scholar 

  155. Moss AJ, Liu JE, Gotlieb S, et al. Efficacy of permanent pacing in the management of the long QT syndrome. Circulation 1990; 82 Suppl. III: 181

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Innere Medizin III, Medizinische Universitätsklinik Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany

    Thomas S. Faber, Manfred Zehender & Hanjörg Just

Authors
  1. Thomas S. Faber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manfred Zehender
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hanjörg Just
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Faber, T.S., Zehender, M. & Just, H. Drug-Induced Torsade de Pointes. Drug-Safety 11, 463–476 (1994). https://doi.org/10.2165/00002018-199411060-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199411060-00007

Keywords

Search

Navigation